Covid cases in decline, third wave peak crossed on January 21: Govt

Daily nos. still over 100,000, don't lower guard, health ministry cautions

Topics
Coronavirus Vaccine | Coronavirus | Omicron

Ruchika Chitravanshi  |  New Delhi 

vaccination
The health ministry said the Covid situation in the country was improving even though there were pockets of high case load

With the Covid trajectory of the third wave in decline for the past two weeks, the said on Thursday that the cases peaked at 347,245 on January 21 — at a level lower compared to the second wave peak when daily cases had touched 414,188.

“We don’t talk in terms of waves but only present the data as we see it. Daily cases are declining but are still over 100,000, which means we have to be very careful,” said Lav Agarwal, joint secretary, India registered over 172,000 new Covid infections in the last 24 hours.

The government also said that the Budget allocation of Rs 5,000 crore towards for 2022-23 was an upfront provision. “It has been stated that more resources will be made available as per need,” said V K Paul, member-health Niti Aayog and head of the National Task Force on Covid-19. Paul was responding to a question on whether the lower allocation meant that the government might pull out of free and whether the amount was sufficient for booster shots and children

The Centre had allocated Rs 35,000 cr­ore for vaccinationn in last year’s Budget, which was increased to Rs 39,000 crore in the Revised Estimates for 2021-22.

The said the Covid situation in the country was improving even though there were pockets of high case load. While 34 states are recording a decline in both cases and positivity rate, two states — Kerala and Mizoram — are registering a spike on both counts. The positivity rate in Kerala for the week ending February 3 was 47 per cent, while for Mizo­ram it was 34.1 per cent.

Overall, week-on-week comparison shows a decline in the number of districts with more than 10 per cent positivity — 297 during the last week compared to 406 the week before. And, 169 districts are now reporting a positivity rate between 5 and 10 per cent.

Vaccination reduced mortality

A study of national clinical registry done by the Indian Council of Medical Research, comparing one month of wave and the preceding one month dominated by the Delta variant, showed that complications were much less in the former and that mortality was lower in vaccinated patients.

chart

Ten per cent of the total hospital-admitted patients who died were fully vaccinated and over 90 per cent of them had some comorbidity. Deaths were higher among the unvaccinated at almost 22 per cent and about 83 per cent of them had some comorbidity. Oxygen and mechanical ventilation requirement was also much less in vaccinated individuals compared to the unvaccinated.

The study was conducted on 1,520 individuals admitted in 37 hospitals across the country.

It also found that there were more younger inpatients of around 44 years as against 55-plus in the second wave. And sore throat was more common this time around. Fewer patients had breathing difficulty, fever and cough compared to the Delta wave. Loss of smell or taste, too, was seen in only 2.2 per cent of the patients in the ongoing spread.

Elective surgery safe

Another study by the All India Institute of Medical Sciences (AIIMS) found that unlike the evidence during the earlier surge, with the current variant, surgery is safe and not as­s­ociated with higher chances of complications or deaths in Covid-19-positive patients. “Patients who need surgery need not be denied surgical intervention presently,” the study said.

Of the 53 patients who were part of the study, 60 per cent were given regular anaesthesia. Of these 32 patients, 26 cases were lower segment cesarean section and did not report complications during surgery and immediate postoperative period.

Four deaths were recorded among patients given general anaesthesia, but the study said, “All reported deaths were primarily due to other causes and not lin­­ked or aggravated due to Covid infection.”

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Thu, February 03 2022. 23:03 IST
RECOMMENDED FOR YOU